CSPIA
ABBV icon

Cary Street Partners Investment Advisory’s AbbVie ABBV Stock Holding History

Cary Street Partners Investment Advisory’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Buy
9,052
+911
+11% +$196K 0.46% 52
2026
Q1 		$1.77M Buy
8,141
+248
+3% +$55K 0.45% 57
2025
Q4 		$1.8M Buy
7,893
+831
+12% +$189K 0.49% 55
2025
Q3 		$1.64M Buy
7,062
+253
+4% +$51.5K 0.68% 27
2025
Q2 		$1.26M Sell
6,809
-92
-1% -$17.1K 0.61% 34
2025
Q1 		$1.45M Buy
6,901
+621
+10% +$121K 0.83% 25
2024
Q4 		$1.12M Sell
6,280
-123,590
-95% -$22.7M 0.73% 30
2024
Q3 		$25.6M Buy
129,870
+3,952
+3% +$738K 0.95% 16
2024
Q2 		$21.6M Buy
125,918
+3,822
+3% +$633K 0.87% 19
2024
Q1 		$22.2M Buy
122,096
+1,712
+1% +$295K 0.94% 16
2023
Q4 		$18.7M Buy
120,384
+1,930
+2% +$281K 0.89% 18
2023
Q3 		$17.7M Buy
118,454
+25,813
+28% +$3.79M 0.95% 16
2023
Q2 		$12.5M Buy
92,641
+1,539
+2% +$226K 0.8% 25
2023
Q1 		$14.5M Sell
91,102
-127
-0.1% -$19.4K 1.04% 13
2022
Q4 		$14.7M Sell
91,229
-2,091
-2% -$321K 1.09% 15
2022
Q3 		$12.5M Buy
93,320
+7,123
+8% +$1.02M 1.03% 22
2022
Q2 		$13.2M Buy
86,197
+70,250
+441% +$10.7M 1.12% 14
2022
Q1 		$2.58M Sell
15,947
-1,434
-8% -$208K 0.71% 38
2021
Q4 		$2.35M Buy
17,381
+4,131
+31% +$488K 0.65% 45
2021
Q3 		$1.43M Sell
13,250
-248
-2% -$28.3K 0.47% 67
2021
Q2 		$1.52M Buy
13,498
+5,710
+73% +$643K 0.49% 62
2021
Q1 		$843K Sell
7,788
-12,972
-62% -$1.39M 0.35% 73
2020
Q4 		$2.22M Sell
20,760
-47,184
-69% -$4.53M 0.43% 54
2020
Q3 		$5.95M Buy
67,944
+64,174
+1,702% +$6.04M 1.26% 12
2020
Q2 		$370K Buy
3,770
+411
+12% +$36.2K 0.52% 55
2020
Q1 		$255K Buy
3,359
+336
+11% +$28.6K 0.6% 48
2019
Q4 		$268K Buy
+3,023
New +$251K 0.29% 95
2018
Q4 		$279K Buy
+3,033
New +$267K 0.27% 70

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return

Cary Street Partners Investment Advisory's ABBV Position: Q2 2026 in Review

Cary Street Partners Investment Advisory increased its AbbVie (ABBV) stake by 11% in Q2 2026, buying an estimated $196K and bringing the position to 9,052 shares worth $2.28M. The position accounts for 0.46% of the portfolio, ranked #52.

Cary Street Partners Investment Advisory first reported a position in ABBV in Q4 2018 and has held it in 28 quarters since. The position peaked at $25.6M in Q3 2024. 3,258 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Cary Street Partners Investment Advisory held 9,052 shares of AbbVie worth $2.28M as of Q2 2026.
  • Cary Street Partners Investment Advisory bought 911 AbbVie shares in Q2 2026, an estimated $196K.
  • AbbVie made up 0.46% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #52 holding.
  • Cary Street Partners Investment Advisory first reported a position in AbbVie in Q4 2018 and has held it in 28 quarters since.
  • Cary Street Partners Investment Advisory's AbbVie position peaked at $25.6M in Q3 2024.
  • 3,258 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.